Legend Biotech Stock Rises 18% on Analyst Upgrades and Eli Lilly's Acquisition
Legend Biotech (LEGN) surged 18% on Monday, outperforming the broader market, driven by analyst upgrades and news of Eli Lilly's $7 billion acquisition of Kelonia Therapeutics. The stock's performance was supported by positive developments in its oncology drug pipeline and CAR-T therapy research.
Topics: acquisition analyst recommendations biotech CAR-T therapy stock price movement